Chiu, Tai-JanTai-JanChiuSHIH-HUNG YANGChiu, Sz-ChiSz-ChiChiuHsueh, Shun-WenShun-WenHsuehChiang, Nai-JungNai-JungChiangLi, Chung-PinChung-PinLiBai, Li-YuanLi-YuanBaiCheng, Fu-MingFu-MingChengChuang, Shih-ChangShih-ChangChuangShan, Yan-ShenYan-ShenShanChan, De-ChuanDe-ChuanChanChen, Li-TzongLi-TzongChenYen, Chia-JuiChia-JuiYenPeng, Cheng-MingCheng-MingPengSu, Yung-YehYung-YehSuChen, Yen-YangYen-YangChenChen, Jen-ShiJen-ShiChenChou, Wen-ChiWen-ChiChou2022-10-312022-10-312022-061868-6974https://scholars.lib.ntu.edu.tw/handle/123456789/624301Recent studies have suggested the suboptimal efficacy of liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients previously treated with conventional irinotecan. This study investigated the effect of conventional irinotecan treatment in mPDAC patients receiving nal-IRI+5-FU/LV by analyzing a population-based dataset.enconventional irinotecan; liposomal irinotecan; outcome; pancreatic cancer; propensity score matching[SDGs]SDG3journal article10.1002/jhbp.1128351820312-s2.0-85125502300WOS:000762848300001https://api.elsevier.com/content/abstract/scopus_id/85125502300